Author

Henry E. Pelish

Observed names: H. Pelish, H.E. Pelish, Henry E Pelish, Henry Pelish, Henry E. Pelish

Institution: Nuvalent, Inc. (United States)

Observed institutions: Howard Hughes Medical Institute, Harvard University, Nuvalent, Inc. (United States)

ORCID: 0000-0003-2940-0326

Observed ORCID: 0000-0003-2940-0326

OpenAlex ID: A5074480973

Use of Dynasore, the Small Molecule Inhibitor of Dynamin, in the Regulation of Endocytosis

2008 · Tom Kirchhausen, Eric Macia, et al. · Methods in enzymology on CD-ROM/Methods in enzymology · 465

Mediator kinase inhibition further activates super-enhancer-associated genes in AML

2015 · Henry E. Pelish, Brian B. Liau, et al. · Nature · 410

Use of Biomimetic Diversity-Oriented Synthesis to Discover Galanthamine-Like Molecules with Biological Properties beyond Those of the Natural Product

2001 · Henry E. Pelish, Nicholas J. Westwood, et al. · Journal of the American Chemical Society · 209

Identification of Mediator Kinase Substrates in Human Cells using Cortistatin A and Quantitative Phosphoproteomics

2016 · Zachary C. Poss, Christopher C. Ebmeier, et al. · Cell Reports · 172

PDF

Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro

2005 · Henry E Pelish, Jeffrey R Peterson, et al. · Nature Chemical Biology · 166

An Alkylsilyl-Tethered, High-Capacity Solid Support Amenable to Diversity-Oriented Synthesis for One-Bead, One-Stock Solution Chemical Genetics

2001 · John A. Tallarico, Kris M. Depew, et al. · Journal of Combinatorial Chemistry · 107

Biochemical Suppression of Small-Molecule Inhibitors: A Strategy to Identify Inhibitor Targets and Signaling Pathway Components

2006 · Jeffrey R. Peterson, Andres M. Lebensohn, et al. · Chemistry & Biology · 85

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

2024 · Jessica J. Lin, Joshua C. Horan, et al. · Cancer Discovery · 69

NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations

2022 · Alexander Drilon, Joshua C. Horan, et al. · Cancer Discovery · 55

Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation

2017 · Ioana I. Nitulescu, Sara C. Meyer, et al. · EBioMedicine · 55

PDF

The Selectivity of Austocystin D Arises from Cell-Line-Specific Drug Activation by Cytochrome P450 Enzymes

2011 · Kevin M. Marks, Eun Sun Park, et al. · Journal of Natural Products · 45

PDF

Abstract 1468: NUV-655 (NVL-655) is a selective, brain-penetrant ALK inhibitor with antitumor activity against the lorlatinib-resistant G1202R/L1196M compound mutation

2021 · Henry E. Pelish, Anupong Tangpeerachaikul, et al. · Cancer Research · 26

Large scale synthesis of the Cdc42 inhibitor secramine A and its inhibition of cell spreading

2006 · Bo Xu, Henry Pelish, et al. · Organic & Biomolecular Chemistry · 26

STAT3 Inhibitory Activity of Structurally Simplified Withaferin A Analogues

2017 · Teruyuki Tahara, Ursula Streit, et al. · Organic Letters · 23

The Cdc42 inhibitor secramine B prevents cAMP-induced K+ conductance in intestinal epithelial cells

2006 · Henry E. Pelish, William Ciesla, et al. · Biochemical Pharmacology · 12

PDF

Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations

2025 · Anupong Tangpeerachaikul, Scot Mente, et al. · Molecular Cancer Therapeutics · 10

PDF

81TiP NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: The phase I/II ALKOVE-1 study

2023 · M.L. Johnson, S-H.I. Ou, et al. · Journal of Thoracic Oncology · 8

PDF

Abstract 1979: Preclinical characterization of NVL-330, a selective and brain penetrant HER2 tyrosine kinase inhibitor with broad activity on HER2 oncogenic alterations

2024 · Yuting Sun, Kristin L. Andrews, et al. · Cancer Research · 4

Abstract P244: NVL-655 exhibits antitumor activity in lorlatinib-resistant and intracranial models of ALK-rearranged NSCLC

2021 · Anupong Tangpeerachaikul, Amit Deshpande, et al. · Molecular Cancer Therapeutics · 4

Abstract 1465: NUV-520 (NVL-520) is a brain-penetrant and highly selective ROS1 inhibitor with antitumor activity against the G2032R solvent front mutation

2021 · Henry E. Pelish, Anupong Tangpeerachaikul, et al. · Cancer Research · 4

CDK8 /19 inhibition triggers a switch from mitosis to endomitosis in cord blood megakaryocytes

2024 · Zhi‐Jian Liu, Christopher Thom, et al. · British Journal of Haematology · 2

PDF

Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation

2022 · T. Fujino, L. Nguyen, et al. · European Journal of Cancer · 2

PDF

EP08.02-020 Preclinical Activity of NVL-655 in a Patient-Derived NSCLC Model with Lorlatinib-Resistant ALK G1202R/T1151M Mutation

2022 · H. Mizuta, L. Bigot, et al. · Journal of Thoracic Oncology · 2

PDF

Abstract 3337: Preclinical activity of NVL-655 in ALK-driven cancer models beyond non-small cell lung cancer

2022 · Anupong Tangpeerachaikul, Ludovic Bigot, et al. · Cancer Research · 2

Abstract LB366: Zidesamtinib has differentiated preclinical brain penetrance and intracranial activity compared to other ROS1 inhibitors

2026 · Anupong Tangpeerachaikul, Joshua C. Horan, et al. · Cancer Research · 1

Works count: 66

Citation count: 1,972

H-index: 14

I10-index: 16